<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Medical and Social Expert Evaluation and Rehabilitation</journal-id><journal-title-group><journal-title xml:lang="en">Medical and Social Expert Evaluation and Rehabilitation</journal-title><trans-title-group xml:lang="ru"><trans-title>Медико-социальная экспертиза и реабилитация</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9537</issn><issn publication-format="electronic">2412-2092</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">544172</article-id><article-id pub-id-type="doi">10.17816/MSER544172</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Effectiveness of a novel hydrolysate collagen formulation in the complex treatment and rehabilitation of patients with symptomatic knee osteoarthritis</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность применения нового состава гидролизата коллагена в комплексном лечении и реабилитации пациентов c симптоматическим остеоартрозом коленного сустава</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0758-4590</contrib-id><name-alternatives><name xml:lang="en"><surname>Repetyuk</surname><given-names>Aleksey D.</given-names></name><name xml:lang="ru"><surname>Репетюк</surname><given-names>Алексей Дмитриевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>md, cand. sci. (med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>repetyuk_a_d@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2378-8163</contrib-id><name-alternatives><name xml:lang="en"><surname>Ternovoy</surname><given-names>Konstantin S.</given-names></name><name xml:lang="ru"><surname>Терновой</surname><given-names>Константин Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>md, cand. sci. (med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>ternovoy_k_s@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-11-23" publication-format="electronic"><day>23</day><month>11</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2023</year></pub-date><volume>26</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>111</fpage><lpage>120</lpage><history><date date-type="received" iso-8601-date="2023-07-10"><day>10</day><month>07</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-11-02"><day>02</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-12-15"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjmseer.com/1560-9537/article/view/544172">https://rjmseer.com/1560-9537/article/view/544172</self-uri><abstract xml:lang="en"><p>BACKGROUND: Knee osteoarthritis is a chronic disease that can eventually lead to surgical arthroplasty. Overuse, inflammation, metabolic disorders, and hormonal changes play important roles in the pathogenetic development of osteoarthritis of the knee. Recent studies have shown that collagen hydrolysate slows down the degenerative processes in cartilage tissue and has analgesic and anti-inflammatory effects.</p> <p>AIMS: To examine the effect of a dietary supplement of collagen hydrolysate (COLLA GEN) on the treatment and rehabilitation of patients with symptomatic knee osteoarthritis.</p> <p>MATERIALS AND METHODS: This prospective, blinded, placebo-controlled study included 99 patients diagnosed with radiographic knee osteoarthritis. All patients were randomly divided into two groups. Both groups were prescribed a course of therapeutic exercises. Group I was also prescribed a food supplement of collagen hydrolysate (COLLA GEN), whereas group II received placebo. The effectiveness of collagen hydrolysate in symptomatic osteoarthritis was evaluated based on the comparison of the WOMAC and VAS scores before the treatment and rehabilitation process and after 1, 3, and 6 months.</p> <p>RESULTS: Daily intake of 40 g of collagen hydrolysate dietary supplement of collagen hydrolysate («COLLA GEN») for 3 months, in combination with exercise therapy, in patients with symptomatic osteoarthritis, allowed statistically significant (p &lt;0.05), compared with the placebo group, to improve such indicators on the WOMAC scale as «pain» (3.9±1.5 in group I and 5.4±1.8 in group II), «physical function» (8.7±3.2 in group I and 13.7±2.9 in group II), and «total score» (14.5±5.2 in group I and 21.5±4.9 in group II) by 6 months of observation. When analyzing the indicators on the VAS scale at the end of the 3<sup>rd </sup>and<sup> </sup>6<sup>th</sup> month of treatment, a statistically significant difference (p &lt;0.05) was observed between the indicators of regression of pain symptoms, which were 2.17 and 3.72 points in group I and 0.83 and 2.03 points in group II, respectively.</p> <p>CONCLUSION: The use of a novel hydrolysate collagen formulation in the complex treatment and rehabilitation of patients with symptomatic knee osteoarthritis has potential therapeutic effects.</p></abstract><trans-abstract xml:lang="ru"><p>Обоснование. Остеоартроз коленного сустава является хроническим заболеванием, которое в исходе может привести к необходимости хирургического эндопротезирования. Важную роль в патогенетическом развитии остеоартроза коленного сустава играют локальная механическая перегрузка, воспаление, метаболические нарушения и гормональные изменения. Недавние исследования показывают, что приём гидролизата коллагена замедляет дегенеративные процессы в хрящевой ткани. Также гидролизат коллагена обладает обезболивающими и противовоспалительными свойствами.</p> <p>Цель. Изучить влияние пищевой добавки гидролизата коллагена «Первый живой коллаген (COLLA GEN)» на результаты лечения и реабилитации пациентов c симптоматическим остеоартрозом коленного сустава.</p> <p>Материалы и методы.<bold> </bold>В настоящем проспективном слепом плацебо-контролируемом исследовании участвовали 99 пациентов с установленным при помощи рентгенографии диагнозом «остеоартроз коленного сустава». Все пациенты методом случайной выборки были разделены на две группы. Пациентам обеих групп назначали курс лечебной физической культуры. В I группе наблюдаемым дополнительно назначали приём пищевой добавки гидролизата коллагена «Первый живой коллаген (COLLA GEN)». Во II группе больные получали плацебо. Оценку эффективности приёма гидролизата коллагена при симптоматическом остеоартрозе проводили на основе сравнения результатов показателей по шкале индекса выраженности остеоартроза Университетов Западного Онтарио и МакМастера WOMAC и визуально-аналоговой шкале ВАШ перед началом лечебно-реабилитационного процесса, а также через 1, 3 и 6 месяцев.</p> <p>Результаты.<bold> </bold>Ежедневный приём 40 граммов пищевой добавки гидролизата коллагена «Первый живой коллаген (COLLA GEN)» в течение 3 месяцев в сочетании с курсом лечебной физической культуры у пациентов с симптоматическим остеоартрозом позволял статистически значимо (<italic>р</italic> &lt;0,05) по сравнению с группой плацебо улучшать такие показатели шкалы WOMAC, как «боль» (3,9±1,5 в I группе и 5,4±1,8 во II группе), «функциональное состояние» (8,7±3,2 в I группе и 13,7±2,9 во II группе) и «общий балл» (14,5±5,2 в I группе и 21,5±4,9 во II группе), на 6-м месяце наблюдения. При анализе показателей ВАШ в конце 3-го и 6-го месяцев лечения наблюдали статистически значимую разницу (<italic>р</italic> &lt;0,05) между показателями регресса болевой симптоматики, которые составили –2,17 и –3,72 балла в I группе и –0,83 и –2,03 балла во II группе соответственно.</p> <p>Заключение. Приём нового состава гидролизата коллагена в комплексном лечении и реабилитации пациентов c симптоматическим остеоартрозом коленного сустава обладает потенциальным терапевтическими эффектом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>collagen</kwd><kwd>collagen hydrolysate</kwd><kwd>osteoarthritis</kwd><kwd>knee joint</kwd><kwd>rehabilitation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>коллаген</kwd><kwd>гидролизат коллагена</kwd><kwd>остеоартроз</kwd><kwd>коленный сустав</kwd><kwd>реабилитация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819–828. doi: 10.1136/annrheumdis-2019-216515</mixed-citation><mixed-citation xml:lang="ru">Safiri S., Kolahi A.A., Smith E., et al. Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017 // Ann Rheum Dis. 2020. Vol. 79, № 6. P. 819–828. doi: 10.1136/annrheumdis-2019-216515</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Novakov VB, Novakova ON, Churnosov MI. Risk factors and molecular entities of the etiopathogenesis of the knee osteoarthritis (literature review). Genij ortopedii. 2021;27(1):112–120. doi: 10.18019/1028-4427-2021-27-1-112-120</mixed-citation><mixed-citation xml:lang="ru">Новаков В.Б., Новакова О.Н., Чурносов М.И. Факторы риска и молекулярные основы этиопатогенеза остеоартроза коленного сустава (обзор литературы) // Гений ортопедии. 2021. Т. 27, № 1. С. 112–120. doi: 10.18019/1028-4427-2021-27-1-112-120</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Mazurov VI, Trofimova AS, Trofimov EA. Risk factors and some aspects of the osteoarthritis pathogenesis. Herald of the Northwestern State Medical University named after I.I. Mechnikov. 2016;8(2):116–124.</mixed-citation><mixed-citation xml:lang="ru">Мазуров В.И., Трофимова А.С., Трофимов Е.А. Факторы риска и некоторые аспекты патогенеза остеоартрита // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2016. Т. 8, № 2. С. 116–124.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Lisitsyna EM, Lisitsyn MP, Zaremuk AM. Modern approach to the understanding of pathogenesis, diagnosis and treatment of knee osteoarthrosis. Endoskopicheskaya khirurgiya. 2016;22(6):57–67. (In Russ). doi: 10.17116/endoskop201622657-67</mixed-citation><mixed-citation xml:lang="ru">Лисицина Е.М., Лисицин М.П., Заремук А.М. Современный подход к патогенезу, диагностике и лечению остеоартроза коленного сустава // Эндоскопическая хирургия. 2016. Т. 22, № 6. С. 57–67. doi: 10.17116/endoskop201622657-67</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Geyer M, Schönfeld C. Novel insights into the pathogenesis of osteoarthritis. Curr Rheumatol Rev. 2018;14(2):98–107. doi: 10.2174/1573397113666170807122312</mixed-citation><mixed-citation xml:lang="ru">Geyer M., Schönfeld C. Novel insights into the pathogenesis of osteoarthritis // Curr Rheumatol Rev. 2018. Vol. 14, № 2. P. 98–107. doi: 10.2174/1573397113666170807122312</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Liu S, Yang H, Hu B, et al. Regulates apoptosis and extracellular matrix degradation in resveratrol-treated osteoarthritis chondrocytes via the Wnt/β-catenin signaling pathways. Exp Ther Med. 2017;14(5):5057–5062. doi: 10.3892/etm.2017.5165</mixed-citation><mixed-citation xml:lang="ru">Liu S., Yang H., Hu B., et al. Regulates apoptosis and extracellular matrix degradation in resveratrol-treated osteoarthritis chondrocytes via the Wnt/β-catenin signaling pathways // Exp Ther Med. 2017. Vol. 14, № 5. P. 5057–5062. doi: 10.3892/etm.2017.5165</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Rezuş E, Burlui A, Cardoneanu A, et al. From pathogenesis to therapy in knee osteoarthritis: bench-to-bedside. Int J Mol Sci. 2021;22(5):2697. doi: 10.3390/ijms22052697</mixed-citation><mixed-citation xml:lang="ru">Rezuş E., Burlui A., Cardoneanu A., et al. From pathogenesis to therapy in knee osteoarthritis: bench-to-bedside // Int J Mol Sci. 2021. Vol. 22, № 5 P. 2697. doi: 10.3390/ijms22052697</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Chow YY, Chin KY. The role of inflammation in the pathogenesis of osteoarthritis. Mediators Inflamm. 2020;2020:8293921. doi: 10.1155/2020/8293921</mixed-citation><mixed-citation xml:lang="ru">Chow Y.Y., Chin K.Y. The role of inflammation in the pathogenesis of osteoarthritis // Mediators inflamm. 2020. Vol. 2020. Р. 8293921. doi: 10.1155/2020/8293921</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Krawetz RJ, Wu YE, Bertram KL, et al. Synovial mesenchymal progenitor derived aggrecan regulates cartilage homeostasis and endogenous repair capacity. Cell Death Dis. 2022;13(5):470. doi: 10.1038/s41419-022-04919-1</mixed-citation><mixed-citation xml:lang="ru">Krawetz R.J., Wu Y.E., Bertram K.L., et al. Synovial mesenchymal progenitor derived aggrecan regulates cartilage homeostasis and endogenous repair capacity // Cell Death Dis. 2022. Vol. 13, № 5. P. 470. doi: 10.1038/s41419-022-04919-1</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Gladkova EV, Mamonova IA, Ulyanov VY. Pathogenetic aspects of immune regulation of bone remodeling processes in the debut of primary osteoarthritis of knee joints. Bulletin of new medical technologies. 2022;29(3):63–66. (In Russ). doi: 10.24412/1609-2163-2022-3-63-66</mixed-citation><mixed-citation xml:lang="ru">Гладкова Е.В., Мамонова И.А., Ульянов В.Ю. Патогенетические аспекты иммунной регуляции процессов ремоделирования костной ткани в дебюте первичного остеоартроза коленных суставов // Вестник новых медицинских технологий. 2022. Т. 29, № 3. С. 63–66. doi: 10.24412/1609-2163-2022-3-63-66</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Achkasov EE, Bezuglov EN, Ul’yanov EN, et al. Application platelet-rich plasma in clinical practice. Biomedicine. 2013;(4):46–59. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Ачкасов Е.Е., Безуглов Э.Н., Егорова О.Н., и др. Применение аутоплазмы, обогащённой тромбоцитами, в клинической практике // Биомедицина. 2013. № 4. С. 46–59.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Volpi P, Zini R, Erschbaumer F, Beggio M, Busilacchi A, Carimati G. Effectiveness of a novel hydrolyzed collagen formulation in treating patients with symptomatic knee osteoarthritis: a multicentric retrospective clinical study. Int Orthop. 2021;45(2):375–380. doi: 10.1007/s00264-020-04616-8</mixed-citation><mixed-citation xml:lang="ru">Volpi P., Zini R., Erschbaumer F., et al. Effectiveness of a novel hydrolyzed collagen formulation in treating patients with symptomatic knee osteoarthritis: a multicentric retrospective clinical study // Int Orthop. 2021. Vol. 45, № 2. P. 375–380. doi: 10.1007/s00264-020-04616-8</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Kurshev VV, Litvinenko AS, Bezuglov EN, et al. Rehabilitation of athletes with diseases and injuries of the musculoskeletal system. Surgical practice. 2015;(3):71–77. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Куршев В.В., Литвиненко А.С., Безуглов Э.Н. Реабилитация спортсменов с заболеваниями и травмами опорно-двигательного аппарата // Хирургическая практика. 2015. № 3. С. 71–77.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kumar S, Sugihara F, Suzuki K, et al. A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis. J Sci Food Agric. 2015;95(4):702–707. doi: 10.1002/jsfa.6752</mixed-citation><mixed-citation xml:lang="ru">Kumar S., Sugihara F., Suzuki K., et al. A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis // J Sci Food Agric. 2015. Vol. 95, № 4. Р. 702–707. doi: 10.1002/jsfa.6752</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Mobasheri A, Mahmoudian A, Kalvaityte U, Uzieliene I, Larder CE, et al. A white paper on collagen hydrolyzates and ultrahydrolyzates: potential supplements to support joint health in Osteoarthritis? Curr Rheumatol Rep. 2021;23(11):78. doi: 10.1007/s11926-021-01042-6</mixed-citation><mixed-citation xml:lang="ru">Mobasheri A., Mahmoudian A., Kalvaityte U., Uzieliene I., Larder C.E., et al. A white paper on collagen hydrolyzates and ultrahydrolyzates: potential supplements to support joint health in Osteoarthritis? // Curr Rheumatol Rep. 2021. Vol. 23, № 11. Р. 78. doi: 10.1007/s11926-021-01042-6</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">León-López A, Morales-Peñaloza A, Martínez-Juárez VM, et al. Hydrolyzed collagen-sources and applications. Molecules. 2019;24(22):4031. doi: 10.3390/molecules24224031</mixed-citation><mixed-citation xml:lang="ru">León-López A., Morales-Peñaloza A., Martínez-Juárez V.M. Hydrolyzed сollagen-sources and applications // Molecules. 2019. Vol. 24, № 22. P. 4031. doi: 10.3390/molecules24224031</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Skov K, Oxfeldt M, Thøgersen R, et al. Enzymatic hydrolysis of a collagen hydrolysate enhances postprandial absorption rate. Nutrients. 2019;11(5):1064. doi: 10.3390/nu11051064</mixed-citation><mixed-citation xml:lang="ru">Skov K., Oxfeldt M., Thøgersen R. Hydrolysis of a collagen hydrolysate enhances postprandial absorption rate // Nutrients. 2019. Vol. 11, № 5. P. 1064. doi: 10.3390/nu11051064</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Trc T, Bohmova J. Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. Glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA). International Int Orthop. 2011;35(3):341–348. doi: 10.1007/s00264-010-1010-z</mixed-citation><mixed-citation xml:lang="ru">Trc T., Bohmova J. Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. Glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA) // International Int Orthop. 2011. Vol. 35, № 3. P. 341–348. doi: 10.1007/s00264-010-1010-z</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Moskowitz RW. Role of Collagen hydrolysate in Bone and Joint disease. Semin Arthritis Rheum. 2000;30(2):87–99. doi: 10.1053/sarh.2000.9622</mixed-citation><mixed-citation xml:lang="ru">Moskowitz R.W. Role of Collagen hydrolysate in Bone and Joint disease // Semin Arthritis Rheum. 2000. Vol. 30, № 2. P. 87–99. doi: 10.1053/sarh.2000.9622</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Watanabe-Kamiyama M, Shimizu M, Kamiyama S, Taguchi Y, Sone H, et al. Absorption and Effectiveness of Orally Administered Low Molecular Weight Collagen Hydrolysate in Rat. J Agric Food Chem. 2010;58(2):835–841. doi: 10.1021/jf9031487</mixed-citation><mixed-citation xml:lang="ru">Watanabe-Kamiyama M., Shimizu M., Kamiyama S., Taguchi Y., Sone H., et al. Absorption and Effectiveness of Orally Administered Low Molecular Weight Collagen Hydrolysate in Rat // J Agric Food Chem. 2010. Vol. 58, № 2. P. 835–841. doi: 10.1021/jf9031487</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Sugihara F, Inoue N, Kuwamori M, Taniguchi M. Quantification of hydroxyprolyl-glycine (Hyp-Gly) in human blood after ingestion of collagen hydrolysate. J Biosci Bioeng. 2012;113(2):202–203. doi: 10.1016/j.jbiosc.2011.09.02</mixed-citation><mixed-citation xml:lang="ru">Sugihara F., Inoue N., Kuwamori M., Taniguchi M. Quantification of hydroxyprolyl-glycine (Hyp-Gly) in human blood after ingestion of collagen hydrolysate // J Biosci Bioeng. 2012. Vol. 113, № 2. P. 202–203. doi: 10.1016/j.jbiosc.2011.09.02</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res. 2003;311(3):393–399. doi: 10.1007/s00441-003-0702-8</mixed-citation><mixed-citation xml:lang="ru">Oesser S., Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen // Cell Tissue Res. 2003. Vol. 311, № 3. P. 393–399. doi: 10.1007/s00441-003-0702-8</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Oesser S, Adam M, Babel W, Seifert J. Oral Administration of 14C Labeled Gelatin Hydrolysate Leads to an Accumulation of Radioactivity in Cartilage of Mice (C57/BL). J Nutr. 1999;129(10):1891–1895. doi: 10.1093/jn/129.10.1891</mixed-citation><mixed-citation xml:lang="ru">Oesser S., Adam M., Babel W., Seifert J. Oral Administration of 14C Labeled Gelatin Hydrolysate Leads to an Accumulation of Radioactivity in Cartilage of Mice (C57/BL) // J Nutr. 1999. Vol. 129, № 10. P. 1891–1895. doi: 10.1093/jn/129.10.1891</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Nakatani S, Mano H, Sampei C, Shimizu J, Wada M. Chondroprotective effect of the bioactive peptide prolyl-hydroxyproline in mouse articular cartilage in vitro and in vivo. Osteoarthr Cartil. 2009;17(12):1620–1627. doi: 10.1016/j.joca.2009.07.001</mixed-citation><mixed-citation xml:lang="ru">Nakatani S., Mano H., Sampei C., Shimizu J., Wada M. Chondroprotective effect of the bioactive peptide prolyl-hydroxyproline in mouse articular cartilage in vitro and in vivo // Osteoarthr Cartil. 2009. Vol. 17, № 12. P. 1620–1627. doi: 10.1016/j.joca.2009.07.001</mixed-citation></citation-alternatives></ref></ref-list></back></article>
